Pharmafile Logo
Pharmafocus logo
Advanced Search

Biocon

Showing 15 posts of 22 posts found.

biocon-k8tc--621x414livemint

India’s National Task Force rejects Biocon’s itolizumab for COVID-19

July 27, 2020
Sales and Marketing Biocon, COVID-19, India, Itolizumab

Biocon was hit with bad news over the weekend as the National Task Force for COVID-19 in its home country …

News
mylan_inside_0

Mylan lands biosimilar sucker punch to Amgen’s blockbuster

June 6, 2018
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta

Mylan and Biocon have received FDA approval for their biosimilar to Amgen’s Neulasta (pegfilgrastim), setting the companies on track to …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

March 16, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Andrew Witty, AstraZeneca, BMS, Biocon, Martin Shkreli, Novartis, Right to try, US, pharma, top ten

Another week goes by, and we may have finally reached Spring here in the UK. Friday means its time for …

News
biocon-k8tc--621x414livemint

FDA inspection reveals cGMP issues at Biocon’s major Malaysia facility

March 13, 2018
Manufacturing and Production Biocon, CGMP, FDA, pharma

Biocon’s insulin production facility in Johar, Malaysia – the largest integrated insulin manufacturing facility in Asia – has been slapped …

News
european_commission_web

EMA committee recommends seven therapies from Roche, GSK, MSD and more

January 29, 2018
Sales and Marketing Biocon, Chiesi, Chugai, GSK, GlaxoSmithKline, MSD, Mylan, Roche, Sanofi, pharma

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has voiced its recommendation of a raft of …

News
sandoz

Novartis enters biosimilar agreement with Biocon

January 19, 2018
Medical Communications, Sales and Marketing Biocon, Novartis, Sandoz, biosimilars, biotech, drugs, pharma, pharmaceutical

Novartis’ Sandoz unit had already staked a claim to being one of the leaders in the developing biosimilar market and …

News
mylan_building

Mylan and Biocon biosimilar approval expands to Brazil

January 2, 2018
Manufacturing and Production, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, pharma, pharmaceutical

Since Mylan and Biocon managed to gain US FDA approval for its Herceptin (Trastuzumab) biosimilar, it has forged ahead in …

News
fdaoutsideweb

Mylan’s Ogivri becomes first and only FDA-approved Herceptin biosimilar

December 4, 2017
Sales and Marketing Biocon, Cancer, FDA, Herceptin, Mylan, Roche, biosimilar, pharma

The FDA has announced the approval of Mylan’s Ogivri (trastuzumab-dkst), the first biosimilar version of Roche’s Herceptin to be authorised …

News
biocon-ltd-hebbagodi-bangalore-ukif4_web

Mylan and Biocon Neulasta biosimilar knocked back by FDA

October 11, 2017
Research and Development, Sales and Marketing Amgen, Biocon, Mylan, Neulasta, biotech, drugs, pharma, pharmaceutical

Mylan and Biocon’s biosimilar version of Amgen’s blockbuster, Neulasta (pegfilgrastim), will have to wait a bit longer before getting the …

News
fda2outsideweb

FDA unanimously recommends Mylan and Biocon’s Herceptin biosimilar

July 14, 2017
Manufacturing and Production, Medical Communications, Sales and Marketing Biocon, Herceptin, Mylan, biosimilar, biotech, drugs, healthcare, life sciences, pharma, pharmaceuticals

Mylan and Biocon have revealed that their biosimilar version of Roche and Genentech’s Herceptin (trastuzumab) has received unanimous recommendation from …

News
shutterstock_2

Problematic facility inspection puts Biocon’s biosimilar EU approvals on hold

July 10, 2017
Manufacturing and Production, Sales and Marketing Biocon, India, biosimilars

Indian firm Biocon has been hit by regulator criticism which has forced its European biosimilar programme on hold following a …

News
biocon_office

Mylan and Biocon apply to FDA for biosimilar approval

January 12, 2017
Sales and Marketing Biocon, FDA, Mylan, biosimilar, trastuzumab

Mylan, the US-based generics specialist, and Biocon, an Indian biopharmaceutical company, have applied for a biologics license application (BLA) for …

News
13bg_fire_at_biocon

Major fire ravages Biocon subsidiary complex in India

December 13, 2016
Manufacturing and Production Biocon, Syngene

A subsidiary of Indian biopharmaceutical firm Biocon was gutted by a major fire at Electronic City, Bangalore on 12 December, …

News
lab

EMA accepts regulatory submission for proposed Herceptin biosimilar

August 26, 2016
Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab

Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …

News

Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial

June 6, 2016
Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab

Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024